Company Profile: Solventum Corporation (SOLV)

SOLV insider trades (13 months) →

$84.76 +0.01% vs. previous close · Market cap $14.43B

Today's multi-factor rank: 63 of 461 · see the ranking

Quant500 Scores

Momentum

6.0/10

Value

5.7/10

Growth

5.2/10

Quality

5.3/10

Multifactor

5.6/10

Market and Valuation

Price & Market

Prev Close Price:$84.75

Open:$84.02

Day's Low:$83.71

Day's High:$85.38

Bid / Ask:-

Market Cap:14.43B

Enterprise Value:19.32B

52-Week Range

52-Week Low:$62.38

52-Week High:$94.16

Current position in 52-week range

52w Low-52w High

50-Day Avg:$88.00

200-Day Avg:$78.39

Volume

Volume Today:1,006,230

Avg Volume (3m):1,042,596

Avg Volume (10d):1,130,100

52-Week Change:+23.56%

vs S&P 500, 52 weeks:-

Beta:0.75

Valuation Multiples

P/E (trailing):10.37

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.

P/E (forward):11.67

PEG Ratio:1.22

Price / Book:3.00

Price / Sales (TTM):1.74

EV / Revenue:2.33

EV / EBITDA:16.96

Dividends

Current yield:-

Annual Dividend Rate:-

Dividend Trailing:$0.00

Yield Trailing:0.00%

5-Year Avg Yield:-

Payout Ratio:0.00%

Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-

Fiscal Year (Next):-

Date Filter (Month):

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):8.31B

Gross Profit:4.55B

EBITDA:1.14B

Net Income (TTM):1.43B

Rev Growth (YoY):+2.20%

Earnings Growth (YoY):+3.90%

Quarterly earnings growth (YoY):+2.20%

Margins

Gross Margin:-

EBITDA Margin:-

Operating Margin:-

Net Margin:-

Per Share

EPS Trailing (TTM):$8.17

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$7.27

Revenue Per Share:$47.79

Cash Per Share:-

Book Value:$28.22

Last Dividend:-

Ex-Dividend Date:-

Last Split:-

Balance Sheet & Liquidity

Total cash:403.00M

Total Debt:5.30B

Net Debt (Debt - Cash):4.89B

Debt / Equity:110.31%

Current Ratio:1.02

Quick Ratio:0.50

Cash Flows

Operating Cash Flow:209.00M

Free Cash Flow (FCF):489.00M

FCF Yield (FCF / Market Cap):-

Enterprise Value:19.32B

EV / Revenue:2.33

EV / EBITDA:16.96

Profitability

ROE (Return on Equity):33.96%

ROA (Return on Assets):2.70%

P/E (trailing):10.37

P/E (forward):11.67

Price / Book:3.00

PEG Ratio:1.22

52-Week Change:+23.56%

S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$8.17

Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 5, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$7.27

P/E (forward):11.67

PEG Ratio:1.22

Growth and Margins

Earnings Growth YoY:-

Quarterly Earnings Growth YoY:-

Rev Growth YoY:-

Net Margin:-

Gross Margin:-

EBITDA Margin:-

Per Share

Revenue Per Share:$47.79

Cash Per Share:-

Book Value:$28.22

Cash Flows (TTM)

Free Cash Flow:489.00M

Operating Cash Flow:209.00M

EBITDA:1.14B

Total Revenue (TTM):8.31B

Net Income (TTM):1.43B

Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter	Period	Actual EPS	Estimated EPS	Difference	Surprise %	Currency

Ownership Structure

Ownership Distribution

% Insiders:-

% Institutional:-

% Inst. (of Float):-

No. of Institutions:-

Visual distribution

InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:170,223,729

Float (free shares):144,089,280

Short interest (shares):4,952,208

Short % of float:-

Short Ratio (days to cover):5.04

Short interest, prior month:-

Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-

Audit Risk:-

Board risk:-

Compensation Risk:-

Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization	Report Date	% Shares	No. Shares	Value (USD)	Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund	Report Date	% Shares	No. Shares	Value (USD)	Change %

Recent Insider Trades

Executive / Insider	Title	Date	Action	Shares

Options Chain

Expiration Date:

CALLS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

PUTS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

Solventum Corporation (SOLV) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type	Date	Official link
8-K	2026-08-05	View filing ↗
8-K	2026-07-20	View filing ↗
8-K	2026-06-05	View filing ↗
SD	2026-05-29	View filing ↗
8-K	2026-05-27	View filing ↗
8-K	2026-05-20	View filing ↗
8-K	2026-05-05	View filing ↗
DEFA14A	2026-03-27	View filing ↗
8-K	2026-03-24	View filing ↗
10-K	2026-02-27	View filing ↗

Company and Executive Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

General Information

Headquarters:United States

City:Eagan

Employees:20,584

Sector:Healthcare

Industry:Medical Instruments & Supplies

Website:-

Key Executives

Name	Title	Age	Total pay
Mr. Bryan C. Hanson	CEO & Director	58	4.93M
Mr. Wayde D. McMillan	Executive VP & CFO	55	1.97M
Ms. Amy Landucci	Chief Information & Digital Officer	50	1.66M
Ms. Marcela A. Kirberger	Chief Corporate & Legal Affairs Officer & Corporate Secretary	58	1.60M
Ms. Heather L. Knight	Chief Commercial Officer	53	2.26M
Mr. Neil C. Zieselman	Senior VP, Controller & Chief Accounting Officer	49	-
Ms. Amy Wakeham	Senior Vice President of Investor Relations & External Finance Communications	-	-
Ms. Rachel H. Ellingson	Chief Strategy & Corporate Development Officer	55	-

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Solventum Corporation (SOLV): Quantitative Analysis

Name: Factor scores for Solventum Corporation (SOLV)
Creator: Quant500
License: https://quant500.com/legal

Solventum Corporation (SOLV) — Healthcare — Medical Instruments & Supplies. SOLV is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, SOLV has returned +7.0% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

SOLV ranks 63 of 461 on today's multifactor score, and 5 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 0.61, ranked 112 of 494); its weakest is growth (Z 0.13, ranked 126 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

Factor	Z-Score	Rank
Multifactor	0.337	63 of 461
Momentum	0.606	112 of 494 ↑8
Value	0.430	109 of 489
Quality	0.179	147 of 468 =
Growth	0.132	126 of 489

Market data

Metric	Value
Price	$84.76
Market Cap	14.43B
P/E	10.37
Revenue (last 12 months)	8.31B
Price / book	3.00
Book value per share	$28.22
52-week range	$62.38 – $94.16
Dividend yield	0.00%
Beta	0.75
Average volume	1,042,596
Shares outstanding	170.22M
Short interest (% of float)	3.43% (as of Oct 15, 2026)

When does SOLV report earnings? 9 of its last 10, after the close →

What are SOLV insiders doing? 65 transactions filed with the SEC, of them 1 buy, the last one on Sep 1, 2026 →

SOLV latest SEC filings

Annual report (10-K): filed Feb 27, 2026, fiscal year ended Dec 31, 2025 · view the filing on sec.gov
Quarterly report (10-Q): filed Aug 5, 2026, quarter ended Jun 30, 2026 · see its 10-Q filings on sec.gov
Earnings release (8-K): Aug 5, 2026, after the close · view the 8-K on sec.gov

Filing dates on EDGAR, the SEC's public registry. All SOLV filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Solventum (SOLV)

When does Solventum report earnings?

According to Nasdaq's public calendar (checked on Nov 4, 2026), Solventum will report its next earnings on Nov 5, 2026, after the US market closes. The date is announced by the company itself and can change. Of its last 10 earnings announcements: 9 after the close and 1 before the open (SEC filings through Aug 5, 2026). SOLV earnings dates and times, quarter by quarter →

What is Solventum's P/E ratio?

Solventum's P/E (price over earnings per share for the last twelve months) is 10.4 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jun 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Solventum is below its sector median. Healthcare stocks, company by company →

Where does Solventum rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Solventum ranks 63 of 461, and 5 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Solventum insiders bought or sold shares?

The latest open-market purchase of Solventum shares filed with the SEC (Form 4) was on Mar 10, 2026, by a director, for $100k. Nor any open-market sale. In total, from August 2025 through Nov 3, 2026: 1 purchase and 0 sales by directors, officers and large shareholders. All SOLV insider trades →

What sector is Solventum in, and which index?

Solventum is classified in the Healthcare sector (industry: Medical Instruments & Supplies), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

Valuation multiples: P/E, P/B, EV/EBITDA and their trapsWhy the P/E and the price-to-book in the table above cannot be compared across sectors, and what a low P/E can hide.
Value and momentum: the two that have survived bestWhat the value and momentum scores on this page actually measure, and why they are the two factors that have best survived scrutiny.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
Sales growth: the driver that gets overestimated mostWhat sits behind the growth score and the twelve-month revenue, and why it is the number people extrapolate too far most often.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

Company Profile: Solventum Corporation (SOLV)

Market and Valuation

Price & Market

52-Week Range

Volume

Valuation Multiples

Dividends

Valuation Context

Financial Statements TTM (Trailing 12 Months)

Income Statement

Margins

Per Share

Balance Sheet & Liquidity

Cash Flows

Profitability

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

Growth and Margins

Per Share

Cash Flows (TTM)

EPS Surprise History - Last 4 Quarters

Ownership Structure

Ownership Distribution

Shares & Short Interest

Governance Score (1=Best, 10=Worst)

Top Institutional Holders

Top Mutual Funds

Recent Insider Trades

Options Chain

CALLS

PUTS

Sentiment Metrics

Expected move

Solventum Corporation (SOLV) SEC filings: 10-K, 10-Q and 8-K

Company and Executive Profile

General Information

Key Executives

You have seen the engine room

Solventum Corporation (SOLV): Quantitative Analysis

Factor scores

Market data

SOLV latest SEC filings

Frequently asked questions about Solventum (SOLV)

When does Solventum report earnings?

What is Solventum's P/E ratio?

Where does Solventum rank on Quant500?

Have Solventum insiders bought or sold shares?

What sector is Solventum in, and which index?

What is behind these numbers